Clinical evidence for dose tolerance of the central nervous system in hypofractionated radiotherapy
- 71 Downloads
Stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), and stereotactic ablative body radiotherapy (SABR) are commonly used in the treatment of central nervous system (CNS) disease. This study has refined the radiation toxicity estimates for some normal tissues of the CNS based on review and analysis of the clinical evidence for single fraction radiosurgery, hypofractionated SBRT, and conventionally fractionated radiation therapy.
Published guidelines and protocols are reviewed. In the past, many normal tissue tolerances were compiled based on the experience of the investigators and publications in the literature. Some tolerances were determined by modeling or calculation using the existing biological formulas, in particular the linear quadratic (LQ) model. In the present study, the estimate of risk for each dose tolerance limit in some CNS tissues is provided exclusively with normal tissue complication probability (NTCP). The clinical outcomes are compared to understand the difference in biological effect between radiosurgery and radiotherapy.
Normal tissue dose tolerances and the corresponding complication rates are provided for brainstem, optic nerves, cochlea, and spinal cord, including single fraction SRS, five-fraction SBRT, and conventional radiation therapy. Calculation of biologically effective dose (BED) or single fraction equivalent dose (SFED) alone using the LQ model conveys no consensus on the biological effect across different fractionations. Comparison of conventional radiation therapy to brain and spinal cord with single fraction equivalent dose leads to even conflicting clinical outcomes.
Effective differences between single fraction SRS and conventional radiotherapy need to be better understood. The existing biological model might not be valid to predict the radiosurgical outcomes based on conventionally fractionated radiotherapy. However, application of the statistical dose response models of clinical SRS and SBRT outcomes data to selected current dose tolerance guidelines into simple tables can be a clinically useful resource.
KeywordsRadiosurgery Radiotherapy Fractionation Toxicities Biologically effective dose Outcomes
Biologically effective dose
Central nervous system
Gross tumor volume
High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic
Maximum likelihood estimate
N-fraction equivalent dose
Normal tissue complication probability
Quantitative Analysis of Normal Tissue Effects in the Clinic
Radiation therapy oncology group
Stereotactic ablative body radiotherapy
Stereotactic body radiation therapy
Single fraction equivalent dose
Whole brain radiation therapy
Compliance with ethical standards
This work was partially supported by a grant from Accuray.
Conflict of interest
Dr. Kleinberg has received research grants from Novocure, Arbor, Accuray, has performed consulting for Novocure, Accuray, and is on the advisory board for Novocure. Dr. Redmond has received research funding from Elekta AB and Accuray, as well as travel expenses and honorarium for speaking for Accuray. Dr. Grimm developed and holds intellectual property rights to the DVH Evaluator software tool which is an FDA-cleared product in commercial use, and which has been used for this analysis; and has received research grants from Novocure and Accuray. All other authors declare that they have no relevant conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent was not applicable due to the retrospective nature of brain dose tolerance study. All other data was from the published literature.
- 1.Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122Google Scholar
- 2.Emami B, Roeske J, Block A, Welsh JS (2017) The Emami paper 25 years later. J Radiat Oncol 6(1):1–9Google Scholar
- 6.Hiniker SM, Modlin LA, Choi CY, Atalar B, Seiger K, Binkley MS, Harris JP, Liao YJ, Fischbein N, Wang L, Ho A, Lo A, Chang SD, Harsh GR, Gibbs IC, Hancock SL, Li G, Adler JR, Soltys SG (2016) Dose-response modeling of the visual pathway tolerance to single-fraction and hypofractionated stereotactic radiosurgery. Semin Radiat Oncol 26(2):97–104PubMedGoogle Scholar
- 12.Milano MT, Grimm J, Soltys SG, Yorke E, Moiseenko V, Tomé WA, Sahgal A, Xue J, Ma L, Solberg T, Kirkpatrick JP, Constine LS, Flickinger JC, Marks LB, El Naqa I. Single and multi-fraction stereotactic radiosurgery dose tolerances of the optic pathways. Int J Radiat Oncol Biol Phys. [HyTEC issue, In Press]Google Scholar
- 13.Vargo JA, Moiseenko V, Grimm J, Caudell J, Clump DA, Yorke E, Xue J, Vinogradskiy Y, Moros EG, Mavroidis P, Jain S, El Naqa I, Marks LB, Heron DE. Head and neck tumor control probability: radiation dose-volume effects in SBRT for locally-recurrent previously-irradiated head and neck cancer. Int J Radiat Oncol Biol Phys. [HyTEC issue, In Press]Google Scholar
- 14.Ohri N, Tomé WA, Méndez Romero A, Miften M, Ten Haken RK, Dawson LA, Grimm J, Yorke E, Jackson A. Local control following stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys. [HyTEC issue, In Press]Google Scholar
- 15.Miften M, Vinogradskiy Y, Moiseenko V, Grimm J, Yorke E, Jackson A, Tomé WA, Ten Haken R, Ohri N, Méndez Romero A, Goodman KA, Marks LB, Kavanagh B, Dawson LA. Radiation dose-volume effects for liver SBRT. Int J Radiat Oncol Biol Phys. [HyTEC issue, In Press]Google Scholar
- 17.Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Bengua G, Onimaru R, de Josien BA, Lebesque JV, Sonke JJ (2010) Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters. Int J Radiat Oncol Biol Phys 77(5):1596–1603PubMedGoogle Scholar
- 20.Fowler JF, Stern BE (1958) Dose-rate factors in integral dose estimations [letter]. Br J Radiol 31:316Google Scholar
- 23.Hall EJ, Giacca AJ (2012) Radiobiology for the radiologist, 7th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
- 24.Joiner M, Avd K (eds) (2009) Basic clinical radiobiology 4th Edition. Hodder Arnold, Great BritainGoogle Scholar
- 30.Carlone M, Wilkins D, Raaphorst P (2005) The modified linear-quadratic model of Guerrero and Li can be derived from a mechanistic basis and exhibits linear-quadratic-linear behaviour. Phys Med Biol. 50(10):L9–13; author reply L13–5.Google Scholar
- 40.Rao SS, Oh JH, Jackson A, Deasy JO (2014) Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In regard to Brown et al. Int J Radiat Oncol Biol Phys 89(3):692–3Google Scholar
- 45.Emami B, Woloschak G, Small W Jr (2015) Beyond the linear quadratic model: intraoperative radiotherapy and normal tissue tolerance. Transl Cancer Res 4(2):140–147Google Scholar
- 48.Betti OO, Derechinsky YE (1982) Irradiations stereotaxiques multifaisceaux. Neurochirurgie 28:55–56Google Scholar
- 57.Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, Constine LS, Deasy JO (2010) The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 76(3 Suppl):S155–S160PubMedPubMedCentralGoogle Scholar
- 63.Benedict S, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37(8):4078–4101PubMedGoogle Scholar
- 64.Bezhak A, Bradley J, Gaspar L, et al Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. Radiation Therapy Oncology Group 0813. Accessible at: https://www.rtog.org/ClinicalTrials/ProtocolTable.aspx. Accessed 8 Jun 2015
- 65.Videtic G, Singh A, Chang J, et al A randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Radiation Therapy Oncology Group 0915. Accessible at: https://www.rtog.org/ClinicalTrials/ProtocolTable.aspx. Accessed 1 Nov 2012
- 67.Lee N, Garden A, Pfister D, et al. RTOG 0615 A phase II study of concurrent chemoradiotherapy using three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) + bevacizumab (BV) for locally or regionally advanced nasopharyngeal cancerGoogle Scholar
- 68.National Cancer Institute. Common terminology criteria for adverse events v4.0. NIH publication # 09–7473. NCI, NIH, DHHS. May 29, 2009Google Scholar
- 69.Chapman JD, Nahum A (2015) Radiotherapy treatment planning, linear-quadratic radiobiology. CRC Press, Taylor & Francis Group LLC, Boca RatonGoogle Scholar
- 71.Grimm J, Shen C, Redmond KJ, Quon H, Kleinberg LR. Avoiding necrosis in radiosurgery of non-AVM intracranial tumors. ACRO 2017Google Scholar
- 72.Grimm J, Shen CJ, Redmond KJ, Sloan L, Hazell S, Seo Y, Chan L, Nikolaidis D, Moore J, Huang E, Quon H, Bettegowda C, Lim M, Kleinberg LR. Low Risk of Symptomatic Radionecrosis Following Stereotactic Radiosurgery for Multiple Brain Metastases, ASTRO 2017Google Scholar
- 73.Inoue HK, Seto K, Nozaki A, Torikai K, Suzuki Y, Saitoh JI, Noda SE, Nakano T (2013) Three-fraction CyberKnife radiotherapy for brain metastases in critical areas: referring to the risk evaluating radiation necrosis and the surrounding brain volumes circumscribed with a single dose equivalence of 14 Gy (V14). J Radiat Res 54(4):727–735PubMedPubMedCentralGoogle Scholar
- 74.Inoue HK, Sato H, Seto KI, Torikai K, Suzuki Y, Saitoh JI, Noda SE, Nakano T (2014) Five-fraction CyberKnife radiotherapy for large brain metastases in critical areas: impact on the surrounding brain volumes circumscribed with a single dose equivalent of 14 Gy (V14) to avoid radiation necrosis. J Radiat Res 55(2):334–342PubMedGoogle Scholar
- 78.Lunsford LD (2009) Top 25 cited Gamma Knife articles in the Journal of Neurosurgery. J Neurosurg 111(3):1–2Google Scholar
- 79.Depp JG. Personal communication, founding president and CEO, Accuray Incorporated. Accessible via http://quantum.site.nfoservers.com/Joe/. Accessed 12 Aug 2017
- 81.Gardner G, Robertson JH (1988) Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol, Rhinol, Laryngol 97:55–66Google Scholar
- 83.Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR, CPNDS Consortium (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41(12):1345–1349Google Scholar
- 84.Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall’Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA (2018) Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med 378(25):2376–2385PubMedGoogle Scholar
- 87.Rubin P (1967) Clinical oncology for medical students and physicians a multidisciplinary approach. Rochester, American Cancer SocietyGoogle Scholar
- 93.van Luijk P, Faber H, Schippers JM, Brandenburg S, Langendijk JA, Meertens H, Coppes RP (2009) Bath and shower effects in the rat parotid gland explain increased relative risk of parotid gland dysfunction after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 74(4):1002–1005PubMedGoogle Scholar